While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.

UCSF Benioff Children's Hospitals and the UCSF Department of Psychiatry and Behavioral Sciences have been recognized as one ...

UCSF Benioff Children's Hospitals and the UCSF Department of Psychiatry and Behavioral Sciences have been recognized as one ...

For instance, medications that help with the psychological effects of schizophrenia might also help with schizoid personality disorder. Stimulants, which are medications that energize people, and ...

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

While the drug Revestive is covered in other provinces, the Gastrointestinal Society is for it to be covered in B.C. after ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

Sanders came to the hearing with, what he claimed, is a commitment from Cigna, UnitedHealth Group and CVS Health to commit to covering the two drugs even if lower list prices lead to lower rebates.

While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...